Fine-tuning adoptive cell therapy for advanced cancers

(University of California - Los Angeles Health Sciences) Researchers identified a discordant phenomenon in which a subset of patients displayed profoundly decreased expression of the transgenic TCR over time, despite the transgenic TCR being present at the DNA level.